

LETTER OPEN



ACUTE LYMPHOBLASTIC LEUKEMIA

PAX5::AUTS2 childhood B-ALL: a relapse-prone genetic subtype with frequent central nervous system involvement and a poor outcome

Aurélie Caye-Eude^{1,2}, Grazia Fazio^{3,4}, Agata Pastorczak⁵, Judith M. Boer⁶, Doris Steinemann⁷, Debudutta Ganguli⁸, Edwin Sonneveld^{6,9}, Sabrina Haslinger^{10,11}, Lucia D'Andrea¹², Jutta Bradtke¹³, Bruno A. Lopes¹⁴, Marketa Zaliova^{15,16,17}, Gabriele Escherich¹⁸, Margit König^{10,11}, Klaus Fortschegger¹⁰, Andrea Inthal^{10,11}, Irina Stasevich¹⁹, Mariana Emerenciano^{10,20}, Jan Trka^{15,16,17}, Luis Castillo¹², Mayur Parihar^{10,21}, Anthony V. Moorman^{10,22}, Anke K. Bergmann⁷, Monique L. den Boer^{10,23}, Wojciech Młynarski^{10,23}, Giovanni Cazzaniga^{10,23}, Hélène Cavé^{10,23}, Karin Nebral^{10,11}, Dagmar Schinnerl¹⁰ and Sabine Strehl¹⁰✉

© The Author(s) 2024

Leukemia; <https://doi.org/10.1038/s41375-024-02502-5>

TO THE EDITOR:

In childhood and young adolescent B-cell precursor acute lymphoblastic leukemia (B-ALL) *PAX5* is one of the most frequent targets of genetic alterations comprising deletions, intragenic amplifications (*PAX5*^{AMP}), and point mutations as well as rearrangements (*PAX5-r*) with multiple partner genes [1]. *PAX5-r* account for 2–3% of all newly diagnosed B-ALL cases and result in the expression of fusion oncoproteins [1, 2].

Patients with *PAX5-r* tend to have higher relapse and poorer overall survival (OS) rates compared to good-risk genetic groups [3–5]. Recent studies indicate that *PAX5-r* is associated with the *IKZF1*^{plus} copy number alteration (CNA) profile and a rather poor event-free survival (EFS) [3, 5]. In small cohorts of infant B-ALL, *PAX5-r* patients had a worse outcome than those with other non-*KMT2A* genetic subtypes [6, 7].

Most, but not all, cases with *PAX5-r* belong to the *PAX5*-altered (*PAX5alt*) subtype identified by gene expression profiling [1]. *PAX5alt* is associated with an intermediate to poor prognosis with a strong dependence on *IKZF1* codeletion [1, 8, 9]. Despite sharing a distinctive expression signature, the underlying genetic landscape of *PAX5alt* is heterogeneous and various types of *PAX5*

lesions, which differently affect disease biology and outcomes, are merged into a single group [1, 9]. Moreover, *PAX5* is fused to a multitude of different partner genes, and since most of these fusions have been detected only in a few cases [1], the impact of individual *PAX5-r* on outcomes remains to be determined.

In this international study, we collected cases with *PAX5::AUTS2* B-ALL diagnosed over the past decades in patients aged 0–18 years, without any time or study protocol restrictions, to evaluate the prognostic relevance of this rare genetic subtype. In accordance with the Declaration of Helsinki, patients were enrolled in respective clinical trials with written informed consent from their parents or legal guardians, and the use of surplus diagnostic material for research purposes was approved by the institutional review boards of the participating centers.

Patients with a confirmed *PAX5::AUTS2* fusion detected by RT-PCR or a next-generation sequencing (NGS) approach were eligible for inclusion in the study. Additionally, since *PAX5::AUTS2* frequently results from unbalanced der(9)t(7;9)(q11;p13) rearrangements, cases with breakpoints in both *PAX5* and *AUTS2* detected by single nucleotide polymorphism (SNP) array analysis were included without additional molecular genetic verification,

¹Department of Genetics, University Hospital Robert Debré, Paris, France. ²INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université Paris-Cité, Paris, France. ³Tettamanti Center, Fondazione IRCCS, San Gerardo dei Tintori, Monza, Italy. ⁴School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. ⁵Department of Genetic Predisposition to Cancer, Medical University of Łódź, Łódź, Poland. ⁶Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. ⁷Department of Human Genetics, Hannover Medical School, Hannover, Germany. ⁸Administrative-Lead Genomics, Tata Translational Cancer Research Center/Tata Medical Center, Kolkata, India. ⁹Dutch Childhood Oncology Group (DCOG), Utrecht, The Netherlands. ¹⁰St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria. ¹¹Labdia Labordiagnostik, Vienna, Austria. ¹²Department of Pediatric Hematology and Oncology, Hospital Pereira Rossell, Pérez Scremini Foundation, Montevideo, Uruguay. ¹³Universitätsklinikum Gießen und Marburg, Institut für Pathologie, Onkogenetisches Labor Molekularpathologie, Gießen, Germany. ¹⁴Leukemia DataLab, Instituto Nacional de Câncer-INCA, Rio de Janeiro, Brazil. ¹⁵CLIP (Childhood Leukaemia Investigation Prague), Prague, Czech Republic. ¹⁶Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. ¹⁷University Hospital Motol, Prague, Czech Republic. ¹⁸University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ¹⁹NHS North Thames Genomic Laboratory Hub, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. ²⁰Genetics of Acute Leukaemia Laboratory-GenLAB, Instituto Nacional de Câncer-INCA, Rio de Janeiro, Brazil. ²¹Department of Laboratory Haematology and Cytogenetics, Tata Medical Centre, Kolkata, India. ²²Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK. ²³Department of Pediatrics, Oncology and Hematology, Medical University of Łódź, Łódź, Poland. ✉email: sabine.strehl@ccri.at

Received: 18 October 2024 Revised: 28 November 2024 Accepted: 9 December 2024

Published online: 19 December 2024

Table 1. Demographic, clinical, genetic characteristics and outcome of *PAX5::AUTS2* patients.

Age group	Children (>1 year) <i>n</i> = 42	Age <18 months <i>n</i> = 18	Infants (≤1 year) <i>n</i> = 8	All patients <i>n</i> = 50
Gender				
Female	42.9% (18/42)	38.9% (7/18)	25.0% (2/8)	40.0% (20/50)
Male	57.1% (24/42)	61.1% (11/18)	75.0% (6/8)	60.0% (30/50)
Age				
Median age in years (range)	2.3 (1.1–15.5)	1.1 (0.6–1.4)	0.9 (0.6–1.0)	2.0 (0.6–15.5)
≤1 year	–	–	–	16.0% (8/50)
>1–3 years	78.6% (33/42)	–	–	66.0% (33/50)
>4–9 years	16.7% (7/42)	–	–	14.0% (7/50)
≥10 years	4.8% (2/42)	–	–	4.0% (2/50)
WBC 10⁹/L				
Median (range)	40.1 (1.2–537.6)	57.0 (2.7–315.0)	53.0 (3.9–299.7)	40.1 (1.2–537.6)
<20	35.7% (15/42)	27.8% (5/18)	25.0% (2/8)	34.0% (17/50)
≥20	16.7% (7/42)	22.2% (4/18)	25.0% (2/8)	18.0% (9/50)
≥50	47.6% (20/42)	50.0% (9/18)	50.0% (4/8)	48% (24/50)
CNS involvement				
Yes ^a	21.4% (9/42)	33.3% (6/18)	62.5% (5/8)	28.0% (14/50)
No	78.6% (33/42)	66.7% (12/18)	37.5% (3/8)	72.0% (36/50)
IKZF1^{plus}				
Yes	66.7% (26/39)	60.0% (9/15)	33.3% (2/6)	62.2% (28/45)
No	33.3% (13/39)	40.0% (6/15)	66.7% (4/6)	37.8% (17/45)
Unknown	7.1% (3/42)	16.7% (3/18)	25.0% (2/8)	10.0% (5/50)
Prednisone response				
Good	78.8% (26/33)	56.3% (9/16)	62.5% (5/8)	75.6% (31/41)
Poor	21.2% (7/33)	43.8% (7/16)	37.5% (3/8)	24.4% (10/41)
Unknown	21.4% (9/42)	16.7% (2/18)	0.0% (0/8)	18.0% (9/50)
MRD				
FCM day 15 ≥10%	26.3% (5/19)	40.0% (4/10)	50.0% (2/4)	30.4% (7/23)
PCR and/or FCM EOI positive ^b	82.1% (32/39)	64.3% (9/14)	60.0% (3/5)	79.5% (35/44)
MRD EIO ≥5 × 10 ⁻⁴	40.6% (13/32)	44.4% (4/9)	20.0% (1/5)	31.8% (14/44)
MRD EOI <5 × 10 ⁻⁴	65.4% (19/32)	55.6% (5/9)	40.0% (2/5)	47.7% (21/44)
MRD EOI negative	17.9% (7/39)	35.7% (5/14)	20.0% (2/5)	20.5% (9/44)
PCR and/or FCM EOC positive ^c	32.4% (11/34)	25.0% (3/12)	0.0% (0/3)	29.7% (11/37)
Relapse				
Yes	42.9% (18/42)	61.1% (11/18)	62.5% (5/8)	46.0% (23/50)
BM ^d	72.2% (13/18)	63.6% (7/11)	40.0% (2/5)	65.2% (15/23)
CNS	11.1% (2/18)	18.2% (2/11)	20.0% (1/5)	13.0% (3/23)
BM & CNS	16.7% (3/18)	18.2% (2/11)	40.0% (2/5)	21.7% (5/23)
No	57.1% (24/42)	38.9% (7/18)	37.5% (3/8)	54.0% (27/50)
Outcome				
Dead	19.0% (8/42)	27.8% (5/18)	25.0% (2/8)	20.0% (10/50)
Leukemia	37.5% (3/8)	20.0% (1/5)	0.0% (0/2)	30.0% (3/10)
Treatment-related complications	37.5% (3/8)	40.0% (2/5)	50.0% (1/2)	40.0% (4/10)
Other cause/unknown	25.0% (2/8)	40.0% (2/5)	50.0% (1/2)	30.0% (3/10)
Alive	81.0% (34/42)	72.2% (13/18)	75.0% (6/8)	80.0% (40/50)

WBC white blood cell count, CNS central nervous system, MRD measurable residual disease, FCM flow cytometry, EOI end of induction, EOC end of consolidation, BM bone marrow.

^aincluding patients with CNS2, CNS3, traumatic lumbar puncture with leukemia blasts or reported as positive without any further classification.

^bdays 28–42 of therapy.

^cdays 78–112 of therapy.

^done childhood patient had an extramedullary testis involvement.

likewise cases identified by optical genome mapping (OGM). All *PAX5::AUTS2* fusion transcripts were in frame or at least predicted to be. CNA profiling for *IKZF1* deletion and *IKZF1*^{plus} was performed by SNP array, multiplex ligation-dependent probe amplification (MLPA), digitalMLPA or OGM following standard procedures (Supplementary Methods).

The Kaplan–Meier method was used to determine EFS and OS rates and the analysis was performed in R (version 4.2.2) statistical environment. Adverse events were defined as relapse at any site, the development of a second malignant neoplasm (SMN), or death from any cause. OS was defined as the time from diagnosis to the date of last follow-up or death. The cumulative incidence of relapse (CIR) was calculated using the Kalbfleisch and Prentice method and compared with the Gray's test considering death and SMN as competing events. Multivariate analysis was conducted using a Cox proportional hazards regression model.

We identified 50 patients diagnosed with *PAX5::AUTS2* B-ALL, including 16 previously published cases (Supplementary Table S1). The main demographic and clinical features showed a male predominance (60% vs 40%), a median age of 2.0 years (range 0.6–15.5 years), including eight infants (≤ 1 year), and highly variable white blood cell counts (WBC) ranging from $1.2\text{--}537.6 \times 10^9/\text{L}$ (median $40.1 \times 10^9/\text{L}$) (Table 1).

We detected *IKZF1* deletions in 69.6% (32/46 with available data) of *PAX5::AUTS2* cases, most displaying also *CDKN2A/B* (90.0%,

27/30) and/or *PAX5* (87.1%, 27/31) deletions (Supplementary Table S1). Based on this deletion pattern, 62.2% (28/45) showed the *IKZF1*^{plus} CNA profile [10] (Table 1), which is higher than reported for childhood *PAX5alt* (20–30% *IKZF1*-deleted, 20% *IKZF1*^{plus}) or *PAX5*^{AMP} (13% *IKZF1*^{plus}) cases [1, 9, 11].

According to National Cancer Institute (NCI) criteria (age ≥ 10 years and/or $\text{WBC} \geq 50 \times 10^9/\text{L}$; infants), 60.0% (30/50) of patients had high-risk (HR) status. Of the patients with available data, 24.4% (10/41) showed a poor prednisone response (Table 1), which is ~15% higher than in the average population of childhood B-ALL [10]. Measurable residual disease (MRD) data assessed by flow cytometry (FCM) on day 15 were only available for 23 patients, and according to AIEOP-BFM definitions, 30.4% (7/23) showed HR disease with $\geq 10\%$ residual blast cells [12]. At the end of induction therapy (EOI; days 28–42), PCR- and/or FCM-MRD measurements showed that 79.5% (35/44) of patients were MRD-positive: 31.8% (14/44) $\geq 5 \times 10^{-4}$ and 47.7% (21/44) $< 5 \times 10^{-4}$. At the end of consolidation therapy (EOC; mainly day 78; range 71–117 days), 29.7% (11/37) of patients still presented with MRD, but except for two ($\geq 5 \times 10^{-4}$), with levels $\leq 1 \times 10^{-4}$ (Table 1 and Supplementary Table S1).

Overall, 46.0% (23/50) of *PAX5::AUTS2* patients experienced a relapse with a median time-to-event of 1.6 years (range 0.6–4.1 years) with the majority (65.2%, 15/23) occurring within two years after diagnosis (Fig. 1A; Supplementary Table S1). Most patients




Fig. 1 Course of disease and outcome of *PAX5::AUTS2* patients. **A** Swimmer plot illustrating the clinical course of each individual patient. Relapses (orange dots), bone marrow transplantation (BMT; blue triangles), and death (red crosses) as well as age groups <18 months (light brown bars) and ≥ 18 months (gray bars) are indicated. **B–C** Cumulative incidence of relapse (CIR) and Kaplan–Meier survival curves of event-free (EFS) and overall survival (OS), (**B**) of all *PAX5::AUTS2* cases ($n = 50$), (**C**) based on age group; red, <18 months; blue, ≥ 18 months. Gray's test p -value for CIR, Log-ranks test p -values for EFS and OS. **D** Forrest plot showing results of multivariate Cox regression analysis. HR hazard ratio, CI confidence interval, p Gray's test p -value, WBC white blood cell count, NCI-HR National Cancer Institute high-risk, MRD-EOI (measurable residual disease) determined by PCR and/or flow cytometry at the end of induction (EOI) therapy.

had isolated bone marrow (BM; 60.9%, 14/23) relapses, but CNS disease was detected in 34.8% (8/23) of patients mostly combined with BM recurrence (Table 1). In total, 38.0% (19/50) of patients had CNS disease: 22.0% (11/50) only at diagnosis, 6.0% (3/50) at diagnosis and relapse, and 10.0% (5/50) only at relapse. Among infants, 87.5% (7/8) had CNS involvement, with 62.5% (5/8) already at diagnosis (Supplementary Methods), one patient at both time points, and two additional cases only at relapse (Supplementary Table S1). CNS disease was more frequently detected in infants than in children [87.5% (7/8) vs 40.0% (12/30), Fisher exact test $p = 0.0031$].

The 5-year CIR for all patients was $48.0 \pm 7.8\%$ (Fig. 1B) and of the patients who relapsed, 17.4% (4/23) experienced a second BM relapse within 3–9 months of the first (Fig. 1A). Among patients experiencing a relapse, 30.4% (7/23) died, three of progressive disease and four of treatment-related mortality (TRM), and in total, 20.0% (10/50) of patients died ($n = 3$ leukemia, $n = 4$ TRM, $n = 3$ other/unknown reasons) (Fig. 1A, Table 1 and Supplementary Table S1).

With a median follow-up of 4.8 years (range 0.3–13.0 years), we observed 5-year EFS and OS rates for all patients of $47.9 \pm 7.6\%$ and $76.2 \pm 7.1\%$, respectively, (Fig. 1B). Notably MRD levels ($\geq 5 \times 10^{-4}$ vs $< 5 \times 10^{-4}$ vs negative) at EO1 did not significantly impact CIR, EFS or OS (Supplementary Fig. S1A), suggesting that in *PAX5::AUTS2* patients EO1-MRD negativity does not predict a favorable outcome. Patients with $\geq 5 \times 10^{-4}$ EO1-MRD had a worse EFS compared to cases with $< 5 \times 10^{-4}$ /negative EO1-MRD, but the result did not reach statistical significance ($p = 0.057$) (Supplementary Fig. S1B). Furthermore, we did not find any differences in 5-year EFS and OS between *IKZF1*^{plus} and non-*IKZF1*^{plus} patients ($46.6 \pm 9.9\%$ vs $60.6 \pm 14.0\%$, $p = 0.67$; $78.7 \pm 8.5\%$ vs $93.8 \pm 6.1\%$, $p = 0.89$) indicating that also *IKZF1*^{plus} has no predictive value (Supplementary Fig. S1C).

Given that patients were enrolled in various clinical trials with differing risk stratification criteria and treatment regimens, we compared the outcomes between earlier clinical trials and the two most contemporary ones (i.e., AIEOP-BFM ALL 2017, ALLTogether-1) but did not find any significant improvement (Supplementary Fig. S1D).

When comparing the outcomes of children and infants, we observed a higher CIR and consequently a poorer EFS for infant patients (Supplementary Fig. S2A). As several patients were just over 1 year of age (Table 1), we explored whether age influenced the outcome. Our analysis according to different age groups revealed that patients aged < 18 months had a significantly higher 5-year CIR ($68.5 \pm 12.7\%$ vs $36.2 \pm 9.4\%$, $p = 0.006$) and worse outcome (Fig. 1C) than other age groups (Supplementary Figs. S2B–D). In multivariate analysis, EO1-MRD $\geq 5 \times 10^{-4}$ (hazard ratio 15.55, $p = 0.001$) and age (< 18 months vs older; hazard ratio 16.65, $p = 0.001$) had an independent impact on EFS (Fig. 1D).

Collectively, our study demonstrates that childhood *PAX5::AUTS2* B-ALL is characterized by a high frequency of CNS involvement and is a relapse-prone subtype with poor outcomes. The disease mainly affects infants and toddlers with over 80% being less than three years old, which differs from the childhood *PAX5alt* group, which is more common in older patients (children 1–18 years, $n = 94$, median 9.5 years; ST1 cohort [1]) [1, 8, 9]. The observed EFS and OS survival rates for *PAX5::AUTS2* B-ALL were lower than those in the overall *PAX5alt* group but similar to those of patients with *PAX5*^{AMP} [1, 8, 9, 11], underlining the importance of focusing outcome analysis on genetically homogeneous entities with unique alterations.

Our data also support the notion that *PAX5-r* is in general recurrent in infants and along with *KMT2A-r* may represent a further subgroup of infant B-ALL with a potentially dismal outcome, while *NUTM1-r* has a favorable prognosis [6, 7, 13].

The finding that *PAX5::AUTS2* patients enrolled in contemporary trials still exhibit high relapse rates, emphasizes the need to further explore innovative targeted treatment options [3].

Moreover, strategies to mitigate the risk of relapse and treatment-related mortality associated with salvage therapy are needed. Frontline use of the bi-specific T-cell engager blinatumomab, which has been proven to be safe and effective also in infants [14, 15] may be a worthwhile consideration.

DATA AVAILABILITY

The data relevant to this study are provided in Supplementary Table S1. More detailed de-identified patient and genetic data may only be obtained from the relevant clinical trial committees upon reasonable request.

REFERENCES

- Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. *Nat Genet.* 2019;51:296–307.
- Nebtral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. *Leukemia.* 2009;23:134–43.
- Fazio G, Bresolin S, Silvestri D, Quadri M, Saitta C, Vendramini E, et al. PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120. *EBioMedicine.* 2022;83:104224.
- Schwab C, Cranston RE, Ryan SL, Butler E, Winterman E, Hawking Z, et al. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. *Leukemia.* 2023;37:529–38.
- Luhmann JL, Zimmermann M, Hofmann W, Bergmann AK, Moricke A, Cario G, et al. Deciphering the molecular complexity of the IKZF1(plus) genomic profile using optical genome mapping. *Haematologica.* 2024;109:1582–7.
- Fazio G, Bardini M, De Lorenzo P, Grioni A, Quadri M, Pedace L, et al. Recurrent genetic fusions redefine MLL germline acute lymphoblastic leukemia in infants. *Blood.* 2021;137:1980–4.
- Popov A, Tsaur G, Permikin Z, Henze G, Verzhbitskaya T, Plekhanova O, et al. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: results of MLL-Baby protocol. *Pediatr Blood Cancer.* 2023;70:e30204.
- Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. *Blood Cancer Discov.* 2021;2:326–37.
- Li Z, Lee SHR, Chin WHN, Lu Y, Jiang N, Lim EH, et al. Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia. *Blood Adv.* 2021;5:5226–38.
- Stanulla M, Dagdan E, Zaliova M, Moricke A, Palmi C, Cazzaniga G, et al. IKZF1(-plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. *J Clin Oncol.* 2018;36:1240–9.
- Schwab C, Nebtral K, Chilton L, Leschi C, Waanders E, Boer JM, et al. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia? *Blood Adv.* 2017;1:1473–7.
- Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. *J Clin Oncol.* 2009;27:5168–74.
- Boer JM, Valsecchi MG, Hormann FM, Antic Z, Zaliova M, Schwab C, et al. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. *Leukemia.* 2021;35:2978–82.
- van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. *N Engl J Med.* 2023;388:1572–81.
- Lyons KU, Gore L. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia. *Haematologica.* 2024;109:1668–76.

ACKNOWLEDGEMENTS

This study was in part supported by The European Union's H2020 Research and Innovation Program through Grant number 825749 "CLOSER: Childhood Leukemia: Overcoming Distance between South America and Europe Regions" to AVM, JT, LC, SS; the ERA-NET TRANSCAN/European Commission under the 7th Framework Programme (FP7), granted by Fondation ARC (www.fondation-arc.org) to HC; a grant from the Italian Association for Cancer Research (AIRC; IG-2023 n. 29191) to GF; a grant from the Deutsche Kinderkrebsstiftung (DKS 2021.14) to perform Optical Mapping in IKZF1 deleted ALL to DS; co-funded by the EU and the State Budget of Czechia OP JAC, project SALVAGE, No. CZ.02.01.01/00/22_008/0004644 to JT, MZ; AP

and WM were supported by funding from the “Label-free and rapid optical imaging, detection and sorting of leukemia cells” project carried out within the Team-Net programme (POIR.04.04.00-00-16ED/18-00) of the Foundation for Polish Science co-financed by the European Union; BAL received a return research grant (1193718 – BRA – HFSTCAPES-P) from the Alexander von Humboldt Foundation and the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro—FAPERJ (E_13/2023); ME is supported by Brazilian National Counsel of Technological and Scientific Development-CNPq (PQ-310982/2023-5) and Fundação Carlos Chagas Filho de Amparo à Pesquisa-FAPERJ (E-26/201.113/2021) research grants; AVM was supported by a Blood Cancer UK programme grant (15036). The authors gratefully acknowledge the Center for Biological Resources (CRBcancer; BB-0033-00076) of the Robert Debré Hospital and the VIVO biobank in the UK.

AUTHOR CONTRIBUTIONS

SS conceived the study, coordinated the data collection, analyzed data, and wrote the manuscript; ACE, GF, AP, JMB, DS, DG, ES, LD, JB, BAL, MZ, GE, IS, ME, JT, LC, MP, AVM, AKB, MLB, WM, GC, and HC contributed genetic and clinical patient data; SH, AI, and KN analyzed, reviewed and interpreted SNP array data; MK, performed FISH analysis and interpreted data; KF conducted molecular genetic analysis of patient samples; DS interpreted data and conducted outcome analysis. All authors reviewed and approved the final manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This study was conducted in accordance with the ethical standards of the institutional and/or national research committees and with the ethical standards as laid down in the Declaration of Helsinki, and all methods were performed in accordance with the relevant guidelines and regulations. Patients were enrolled in an approved international or national clinical trial with written informed consent from

their parents or legal guardians. The institutional review boards of the participating study groups approved the use of anonymized patient data for research purposes.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41375-024-02502-5>.

Correspondence and requests for materials should be addressed to Sabine Strehl.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2024